Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KFDA To Ban 1000-plus Generic Drugs In New Blow To Korea's Domestic Pharmaceutical Companies, Potential Boost For Innovative Medicines

This article was originally published in PharmAsia News

Executive Summary

SEOUL - As regulators tighten checks for safety and effectiveness on South Korea's generic drugs, they have marked 1,226 products, or 58.5 percent of the 2,095 drugs examined, for elimination from the market
Advertisement

Related Content

KFDA Under Fire Over Dawdle In Fight Against Asbestos-tainted Talc Pills
KFDA Under Fire Over Dawdle In Fight Against Asbestos-tainted Talc Pills
South Korea To Implement cGMPs On OTC Drugs To Prepare For U.S. Free Trade Agreement
South Korea To Implement cGMPs On OTC Drugs To Prepare For U.S. Free Trade Agreement
Advertisement
UsernamePublicRestriction

Register

SC071491

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel